Literature DB >> 19663882

Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential.

Najah Abi-Gerges1, Jean-Pierre Valentin, Chris E Pollard.   

Abstract

BACKGROUND AND
PURPOSE: Evaluation of the potential for delayed ventricular repolarization and proarrhythmia by new drugs is essential. We investigated if dog left ventricular midmyocardial myocytes (LVMMs) that can be used as a preclinical model to assess drug effects on action potential duration (APD) and whether in these cells, short-term variability (STV) or triangulation could predict proarrhythmic potential. EXPERIMENTAL APPROACH: Beagle LVMMs and Purkinje fibres (PFs) were used to record APs. Effects of six reference drugs were assessed on APD at 50% (APD(50)) and 90% (APD(90)) of repolarization, STV(APD), triangulation (ratio APD(90)/APD(50)) and incidence of early afterdepolarizations (EADs) at 1 and 0.5 Hz. KEY
RESULTS: LVMMs provided stable recordings of AP, which were not affected by four sequential additions of dimethyl sulphoxide. Effects of dofetilide, d-sotalol, cisapride, pinacidil and diltiazem, but not of terfenadine, on APD in LVMMs were found to be comparable with those recorded in PFs. LVMMs, but not PFs, exhibited a proarrhythmic response to I(Kr) blockers. Incidence of EADs was not related to differences in AP prolongation or triangulation, but corresponded to beat-to-beat variability of repolarization, here quantified as STV of APD. CONCLUSIONS AND IMPLICATIONS: LVMMs provide a suitable preclinical model to assess the effects of new drugs on APD and also yield additional information about putative indicators of proarrhythmia that add value to an integrated QT/TdP risk assessment. Our findings support the concept that increased STV(APD) may predict drug-induced proarrhythmia.

Entities:  

Mesh:

Year:  2009        PMID: 19663882      PMCID: PMC2823354          DOI: 10.1111/j.1476-5381.2009.00338.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.

Authors:  L M Hondeghem; L Carlsson; G Duker
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

Review 2.  Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Authors:  I Cavero; M Mestre; J M Guillon; E Heuillet; A G Roach
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

3.  Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers.

Authors:  H R Lu; R Mariën; A Saels; F De Clerck
Journal:  J Cardiovasc Electrophysiol       Date:  2001-01

Review 4.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Authors:  W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond
Journal:  Cardiovasc Res       Date:  2003-04-01       Impact factor: 10.787

5.  The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Authors:  G A Gintant; J T Limberis; J S McDermott; C D Wegner; B F Cox
Journal:  J Cardiovasc Pharmacol       Date:  2001-05       Impact factor: 3.105

6.  Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.

Authors:  W J Crumb
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

7.  Detection of proarrhythmia in the female rabbit heart: blinded validation.

Authors:  Luc M Hondeghem; Hua Rong Lu; Koen van Rossem; Fred De Clerck
Journal:  J Cardiovasc Electrophysiol       Date:  2003-03

Review 8.  The dog's role in the preclinical assessment of QT interval prolongation.

Authors:  Michael R Gralinski
Journal:  Toxicol Pathol       Date:  2003 Jan-Feb       Impact factor: 1.902

9.  Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.

Authors:  Péter Biliczki; László Virág; Norbert Iost; Julius Gy Papp; András Varró
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability.

Authors:  Luc M Hondeghem; Peter Hoffmann
Journal:  J Cardiovasc Pharmacol       Date:  2003-01       Impact factor: 3.105

View more
  20 in total

1.  Reducing QT liability and proarrhythmic risk in drug discovery and development.

Authors:  Jean-Pierre Valentin
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

2.  Detachable glass microelectrodes for recording action potentials in active moving organs.

Authors:  Mladen Barbic; Angel Moreno; Tim D Harris; Matthew W Kay
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-05-05       Impact factor: 4.733

3.  Contribution of ion currents to beat-to-beat variability of action potential duration in canine ventricular myocytes.

Authors:  Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Balázs Horváth; Ferenc Ruzsnavszky; Krisztina Váczi; János Magyar; Tamás Bányász; András Varró; Péter P Nánási
Journal:  Pflugers Arch       Date:  2014-08-02       Impact factor: 3.657

Review 4.  Dominant rule of community effect in synchronized beating behavior of cardiomyocyte networks.

Authors:  Kenji Yasuda
Journal:  Biophys Rev       Date:  2020-05-04

Review 5.  Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Authors:  Jean-Pierre Valentin; Chris Pollard; Pierre Lainée; Tim Hammond
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

6.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  The high frequency relationship: implications for torsadogenic hERG blockers.

Authors:  P Champeroux; J Y Le Guennec; S Jude; C Laigot; A Maurin; M L Sola; J S L Fowler; S Richard; J Thireau
Journal:  Br J Pharmacol       Date:  2016-01-14       Impact factor: 8.739

8.  Mexiletine-like cellular electrophysiological effects of GS967 in canine ventricular myocardium.

Authors:  Tamás Hézső; Muhammad Naveed; Csaba Dienes; Dénes Kiss; János Prorok; Tamás Árpádffy-Lovas; Richárd Varga; Erika Fujii; Tanju Mercan; Leila Topal; Kornél Kistamás; Norbert Szentandrássy; János Almássy; Norbert Jost; János Magyar; Tamás Bányász; István Baczkó; András Varró; Péter P Nánási; László Virág; Balázs Horváth
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

9.  Increased short-term variability of the QT interval in professional soccer players: possible implications for arrhythmia prediction.

Authors:  Csaba Lengyel; Andrea Orosz; Péter Hegyi; Zsolt Komka; Anna Udvardy; Edit Bosnyák; Emese Trájer; Gábor Pavlik; Miklós Tóth; Tibor Wittmann; Julius Gy Papp; András Varró; István Baczkó
Journal:  PLoS One       Date:  2011-04-15       Impact factor: 3.240

10.  Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations.

Authors:  P Champeroux; J Thireau; S Judé; C Laigot-Barbé; A Maurin; M L Sola; J S L Fowler; S Richard; J Y Le Guennec
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.